• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Identification of androgen-independent progression-relate gene and its clinical application for gene therapy in the prostate cancer

Research Project

Project/Area Number 12307035
Research Category

Grant-in-Aid for Scientific Research (A)

Allocation TypeSingle-year Grants
Section一般
Research Field Urology
Research InstitutionTeikyo University

Principal Investigator

SATO Naohide  Teikyo University, School of Medicine, Lecturer, 医学部, 講師 (50287017)

Co-Investigator(Kenkyū-buntansha) SHIRASAWA Hiroshi  Chiba University, School of Medicine, Professor, 医学部, 教授 (00216194)
市川 智彦  千葉大学, 医学部, 助教授 (20241953)
Project Period (FY) 2000 – 2003
Project Status Completed (Fiscal Year 2003)
Budget Amount *help
¥33,190,000 (Direct Cost: ¥31,300,000、Indirect Cost: ¥1,890,000)
Fiscal Year 2003: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
Fiscal Year 2002: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
Fiscal Year 2001: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
Fiscal Year 2000: ¥25,000,000 (Direct Cost: ¥25,000,000)
Keywordsprostate cancer / gene therapy / androgen-independent progression / prostate-specific antigen / KAII / CD82 gene / intermittent androgen suppression / cancer-specific survival / quality of life / アンドロゲン非依存癌 / プログレッション / QOLの改善
Research Abstract

We had tried to identity androgen-independent progression-related genes in human prostate cancer by using DNA microarray techniques. As a result, KAI1/CD82 gene seemed a candidate of genes that diminished or lost in the process of androgen-independent progression. We have constructed adenovirus vectors that overexpressed KAI1/CD82 gene, and introduced them into androgen-independent metastatic human prostate cancer PC-3 and DU-145 cells to see inhibitory effects against metastatic ability. Unfortunately, this vector did not fully infected into these human prostate cancer cells.
Intermittent androgen suppression (IAS) had been developed as a new clinical approach to delay androgen-independent progression of human prostate cancer. We have investigated the clinical effect of IAS via multi-center prospective study. Fifty-eight prostate cancer patients were registered and treated with a combination of leuprolide acetate and flutamide for 36 weeks. When serum prostate-specific antigen (PSA) le … More vels at 24 and 32 weeks were less than 4.0 ng/mL, treatment was withheld until PSA reached 15 ng/mL or pre-treatment level. This cycle of on- and off-treatment was repeated until PSA failure or symptomatic progression was observed. Changes in QOL were assessed by a self-assessment questionnaire. Forty-nine patients including 26 stage C and 23 stage D were enrolled. Mean follow-up period was 136.5 weeks. Thirty-one patients finished cycle 1,6 finished cycle 2, and 3 finished cycle 3. Mean off-treatment periods in cycle 1, 2, and 3, were 46.1, 36.9, and 23.3 weeks, respectively. In off-treatment period, significant improvements in QOL score were observed in the categories of potency, physical, social/family, and functional well-being when compared to those in on-treatment period. In conclusion, our analysis indicates that QOL is remarkably improved during off-treatment period. IAS would be a viable option for treatment of advanced prostate cancer, although randomized controlled study is required to determine whether IAS prolongs cancer-specific survival time. Less

Report

(5 results)
  • 2003 Annual Research Report   Final Research Report Summary
  • 2002 Annual Research Report
  • 2001 Annual Research Report
  • 2000 Annual Research Report
  • Research Products

    (4 results)

All 2005 2004

All Journal Article (3 results) Book (1 results)

  • [Journal Article] 前立腺癌の間欠的内分泌療法療法2005

    • Author(s)
      佐藤直秀ほか
    • Journal Title

      Medical Science Digest 31(3)

      Pages: 8-11

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2003 Final Research Report Summary
  • [Journal Article] Intermittent Androgen Suppression for Locally Advanced and Metastatic Prostate Cancer : Preliminary Report of A Prospective Multicenter Study2004

    • Author(s)
      Sato N., et al.
    • Journal Title

      Urology 64(2)

      Pages: 341-345

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2003 Final Research Report Summary
  • [Journal Article] Intermittent androgen suppression for locally advanced and metastatic prostate cancer : preliminary report of a prospective multicenter study.2004

    • Author(s)
      Sato N., Akakura K., Isaka S., Nakatsu H., Tanaka M., Ito H., Masai M., the Chiba Prostate Study Group.
    • Journal Title

      Urology 64

      Pages: 341-345

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2003 Final Research Report Summary
  • [Book] 前立腺癌の間欠的内分泌療法療法 -導入の手引きと最適なプロトコール-2005

    • Author(s)
      赤倉功一郎, 佐藤直秀ほか
    • Total Pages
      170
    • Publisher
      メジカルビュー社
    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2003 Final Research Report Summary

URL: 

Published: 2000-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi